Nektar Therapeutics reports on new alopecia treatment trial results
Nektar Therapeutics 公佈新的禿髮治療臨床試驗結果
Nektar Therapeutics recently shared findings from its Phase 2b REZOLVE-AA trial involving rezpegaldesleukin (REZPEG), a new treatment for severe alopecia areata.
Nektar Therapeutics 最近分享了其REZOLVE-AA 第二b 期臨床試驗的結果，該試驗涉及治療嚴重圓禿（Alopecia areata）的新藥物rezpegaldesleukin（簡稱REZPEG）。
Alopecia areata, which affects 2% of people, often leads to significant hair loss and emotional distress.
圓禿影響了2%的人口，常導致顯著的脫髮及情緒困擾。
This trial tested a novel approach: stimulating regulatory T cells (Tregs) to calm the immune system's attack on hair follicles.
這項試驗測試了一種新穎的方法：藉由刺激調節性T細胞（Tregs）來平息免疫系統對毛囊的攻擊。
While the primary analysis narrowly missed significance, a post-hoc analysis excluding ineligible participants showed a notable 30% reduction in scalp hair loss compared to only 6% for the placebo.
儘管初步分析未達到統計學上的顯著差異，但一項排除了不符合資格參與者的事後分析顯示，與僅有6%的安慰劑組相比，其頭皮脫髮減少了顯著的30%。
The drug appears safe, with very few patients stopping treatment due to side effects.
該藥物看起來相當安全，極少有患者因副作用而停止治療。
With further research, REZPEG could become a vital tool in managing this difficult disease effectively and safely.
透過進一步研究，REZPEG 有望成為有效且安全控制這種棘手疾病的關鍵工具。
